A citation-based method for searching scientific literature

Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
Times Cited: 70







List of co-cited articles
877 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Polyglutamine spinocerebellar ataxias - from genes to potential treatments.
Henry L Paulson, Vikram G Shakkottai, H Brent Clark, Harry T Orr. Nat Rev Neurosci 2017
128
27

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
Hayley S McLoughlin, Lauren R Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G Blumenstein, Hien Zhao, Holly B Kordasiewicz, Vikram G Shakkottai, Henry L Paulson. Ann Neurol 2018
58
25

Spinocerebellar ataxia.
Thomas Klockgether, Caterina Mariotti, Henry L Paulson. Nat Rev Dis Primers 2019
112
20

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
140
18

Scale for the assessment and rating of ataxia: development of a new clinical scale.
T Schmitz-Hübsch, S Tezenas du Montcel, L Baliko, J Berciano, S Boesch, C Depondt, P Giunti, C Globas, J Infante, J-S Kang,[...]. Neurology 2006
907
18

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.
Ronald A M Buijsen, Lodewijk J A Toonen, Sarah L Gardiner, Willeke M C van Roon-Mom. Neurotherapeutics 2019
37
32

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
Maria do Carmo Costa, Katiuska Luna-Cancalon, Svetlana Fischer, Naila S Ashraf, Michelle Ouyang, Rahil M Dharia, Lucas Martin-Fishman, Yemen Yang, Vikram G Shakkottai, Beverly L Davidson,[...]. Mol Ther 2013
65
16

Brain pathology of spinocerebellar ataxias.
Kay Seidel, Sonny Siswanto, Ewout R P Brunt, Wilfred den Dunnen, Horst-Werner Korf, Udo Rüb. Acta Neuropathol 2012
207
15

Neurochemical abnormalities in premanifest and early spinocerebellar ataxias.
James M Joers, Dinesh K Deelchand, Tianmeng Lyu, Uzay E Emir, Diane Hutter, Christopher M Gomez, Khalaf O Bushara, Lynn E Eberly, Gülin Öz. Ann Neurol 2018
34
32

Structural signature of SCA3: From presymptomatic to late disease stages.
Thiago Junqueira Ribeiro Rezende, Jean Levi Ribeiro de Paiva, Alberto Rolim Muro Martinez, Iscia Lopes-Cendes, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Fernando Cendes, Marcondes C França. Ann Neurol 2018
34
32


Toward understanding Machado-Joseph disease.
Maria do Carmo Costa, Henry L Paulson. Prog Neurobiol 2012
153
14

In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7.
Isaac M Adanyeguh, Pierre-Gilles Henry, Tra M Nguyen, Daisy Rinaldi, Celine Jauffret, Romain Valabregue, Uzay E Emir, Dinesh K Deelchand, Alexis Brice, Lynn E Eberly,[...]. Mov Disord 2015
40
25

Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.
Heike Jacobi, Kathrin Reetz, Sophie Tezenas du Montcel, Peter Bauer, Caterina Mariotti, Lorenzo Nanetti, Maria Rakowicz, Anna Sulek, Alexandra Durr, Perrine Charles,[...]. Lancet Neurol 2013
105
14

CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Shuming Ouyang, Yingjun Xie, Zeyu Xiong, Yi Yang, Yexing Xian, Zhanhui Ou, Bing Song, Yuchang Chen, Yuhuan Xie, Haoxian Li,[...]. Stem Cells Dev 2018
27
37

Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards,[...]. N Engl J Med 2019
219
14

Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Edgardo Rodríguez-Lebrón, Maria do Carmo Costa, Katiuska Luna-Cancalon, Therese M Peron, Svetlana Fischer, Ryan L Boudreau, Beverly L Davidson, Henry L Paulson. Mol Ther 2013
70
12

Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease.
Sandro Alves, Isabel Nascimento-Ferreira, Gwennaëlle Auregan, Raymonde Hassig, Noëlle Dufour, Emmanuel Brouillet, Maria C Pedroso de Lima, Philippe Hantraye, Luís Pereira de Almeida, Nicole Déglon. PLoS One 2008
106
12

Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.
Heike Jacobi, Sophie Tezenas du Montcel, Peter Bauer, Paola Giunti, Arron Cook, Robyn Labrum, Michael H Parkinson, Alexandra Durr, Alexis Brice, Perrine Charles,[...]. Lancet Neurol 2015
108
12

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Lauren R Moore, Gautam Rajpal, Ian T Dillingham, Maya Qutob, Kate G Blumenstein, Danielle Gattis, Gene Hung, Holly B Kordasiewicz, Henry L Paulson, Hayley S McLoughlin. Mol Ther Nucleic Acids 2017
61
14

Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7.
Udo Rüb, Ludger Schöls, Henry Paulson, Georg Auburger, Pawel Kermer, Joanna C Jen, Kay Seidel, Horst-Werner Korf, Thomas Deller. Prog Neurobiol 2013
168
12

Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Clévio Nóbrega, Isabel Nascimento-Ferreira, Isabel Onofre, David Albuquerque, Hirokazu Hirai, Nicole Déglon, Luís Pereira de Almeida. PLoS One 2013
78
11

The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies.
Luis Ruano, Claudia Melo, M Carolina Silva, Paula Coutinho. Neuroepidemiology 2014
243
11

Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis.
Ludger Schöls, Peter Bauer, Thorsten Schmidt, Thorsten Schulte, Olaf Riess. Lancet Neurol 2004
649
11

Targeting potassium channels to treat cerebellar ataxia.
David D Bushart, Ravi Chopra, Vikrant Singh, Geoffrey G Murphy, Heike Wulff, Vikram G Shakkottai. Ann Clin Transl Neurol 2018
28
28

Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Silvia Romano, Giulia Coarelli, Christian Marcotulli, Luca Leonardi, Francesca Piccolo, Maria Spadaro, Marina Frontali, Michela Ferraldeschi, Maria Chiara Vulpiani, Federica Ponzelli,[...]. Lancet Neurol 2015
94
11

The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.
H Jacobi, P Bauer, P Giunti, R Labrum, M G Sweeney, P Charles, A Dürr, C Marelli, C Globas, C Linnemann,[...]. Neurology 2011
120
11

Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes.
Isaac M Adanyeguh, Vincent Perlbarg, Pierre-Gilles Henry, Daisy Rinaldi, Elodie Petit, Romain Valabregue, Alexis Brice, Alexandra Durr, Fanny Mochel. Neuroimage Clin 2018
37
21

Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.
Jillian Friedrich, Holly B Kordasiewicz, Brennon O'Callaghan, Hillary P Handler, Carmen Wagener, Lisa Duvick, Eric E Swayze, Orion Rainwater, Bente Hofstra, Michael Benneyworth,[...]. JCI Insight 2018
39
20

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.
Lodewijk J A Toonen, Frank Rigo, Haico van Attikum, Willeke M C van Roon-Mom. Mol Ther Nucleic Acids 2017
49
16

Pathogenesis of SCA3 and implications for other polyglutamine diseases.
Hayley S McLoughlin, Lauren R Moore, Henry L Paulson. Neurobiol Dis 2020
30
26

Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.
Pavitra S Ramachandran, Ryan L Boudreau, Kellie A Schaefer, Albert R La Spada, Beverly L Davidson. Mol Ther 2014
36
19

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
Haibin Xia, Qinwen Mao, Steven L Eliason, Scott Q Harper, Inês H Martins, Harry T Orr, Henry L Paulson, Linda Yang, Robert M Kotin, Beverly L Davidson. Nat Med 2004
485
10


Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.
Alhassane Diallo, Heike Jacobi, Arron Cook, Robyn Labrum, Alexandra Durr, Alexis Brice, Perrine Charles, Cecilia Marelli, Caterina Mariotti, Lorenzo Nanetti,[...]. Lancet Neurol 2018
37
18


Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2.
Kathrin Reetz, Roberto Rodríguez-Labrada, Imis Dogan, Shahram Mirzazade, Sandro Romanzetti, Jörg B Schulz, Edilia M Cruz-Rivas, Jose A Alvarez-Cuesta, Raul Aguilera Rodríguez, Yanetza Gonzalez Zaldivar,[...]. Ann Clin Transl Neurol 2018
25
28

Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy.
Gülin Oz, Isabelle Iltis, Diane Hutter, William Thomas, Khalaf O Bushara, Christopher M Gomez. Cerebellum 2011
45
15

Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6.
Kathrin Reetz, Ana S Costa, Shahram Mirzazade, Anna Lehmann, Agnes Juzek, Maria Rakowicz, Romana Boguslawska, Ludger Schöls, Christoph Linnemann, Caterina Mariotti,[...]. Brain 2013
81
10

Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study.
Anelyssa D'Abreu, Marcondes C França, Clarissa L Yasuda, Bruno A G Campos, Iscia Lopes-Cendes, Fernando Cendes. J Neuroimaging 2012
54
12

Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Philipp Koch, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting,[...]. Nature 2011
221
10

Metabolic and Organelle Morphology Defects in Mice and Human Patients Define Spinocerebellar Ataxia Type 7 as a Mitochondrial Disease.
Jacqueline M Ward, Colleen A Stoyas, Pawel M Switonski, Farid Ichou, Weiwei Fan, Brett Collins, Christopher E Wall, Isaac Adanyeguh, Chenchen Niu, Bryce L Sopher,[...]. Cell Rep 2019
22
31

Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.
O Zhuchenko, J Bailey, P Bonnen, T Ashizawa, D W Stockton, C Amos, W B Dobyns, S H Subramony, H Y Zoghbi, C C Lee. Nat Genet 1997
10

Spinocerebellar ataxia: an update.
Roisin Sullivan, Wai Yan Yau, Emer O'Connor, Henry Houlden. J Neurol 2019
48
14

Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.
A Matilla-Dueñas, T Ashizawa, A Brice, S Magri, K N McFarland, M Pandolfo, S M Pulst, O Riess, D C Rubinsztein, J Schmidt,[...]. Cerebellum 2014
75
8

RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.
Pavitra S Ramachandran, Sajag Bhattarai, Pratibha Singh, Ryan L Boudreau, Stewart Thompson, Albert R Laspada, Arlene V Drack, Beverly L Davidson. PLoS One 2014
26
23

An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron.
Yu Miyazaki, Xiaofei Du, Shin-Ichi Muramatsu, Christopher M Gomez. Sci Transl Med 2016
35
17

Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.
Megan S Keiser, Jeffrey H Kordower, Pedro Gonzalez-Alegre, Beverly L Davidson. Brain 2015
23
26

Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms.
T Schmitz-Hübsch, M Coudert, P Bauer, P Giunti, C Globas, L Baliko, A Filla, C Mariotti, M Rakowicz, P Charles,[...]. Neurology 2008
167
8

Modeling spinocerebellar ataxias 2 and 3 with iPSCs reveals a role for glutamate in disease pathology.
Ching-Yu Chuang, Chih-Chao Yang, Bing-Wen Soong, Chun-Ying Yu, Shu-Hwa Chen, Hsiang-Po Huang, Hung-Chih Kuo. Sci Rep 2019
15
40


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.